Rep. Gilbert Ray Cisneros, Jr. Sells Abbott Laboratories (NYSE:ABT) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on May 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Abbott Laboratories Stock Down 2.3%

Shares of ABT traded down $2.10 during trading hours on Wednesday, hitting $89.15. The company had a trading volume of 11,839,326 shares, compared to its average volume of 11,156,772. The firm has a fifty day moving average price of $92.01 and a 200-day moving average price of $108.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a market capitalization of $155.29 billion, a price-to-earnings ratio of 24.97, a P/E/G ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in ABT. Vanguard Group Inc. grew its stake in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. State Street Corp grew its stake in shares of Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the period. Capital International Investors boosted its stake in Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors boosted its stake in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ABT. BTIG Research reaffirmed a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research report on Monday, April 27th. Barclays decreased their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Raymond James Financial decreased their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Benchmark decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.